WebOct 30, 2024 · → Amassing a nice chunk of change ($133 million) over 3 rounds — including one for $50 million that was announced in June — … WebUnum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor …
Unum Therapeutics Reports Second Quarter 2024 Financial …
WebLeadingBiotech Cancer Advance Boston is a networking forum for CEOs and decision-makers in the life sciences industry. From scientific breakthrough to commercial … WebOct 5, 2024 · --Unum Therapeutics Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its name change to Cogent Biosciences, Inc.. Cogent is ... grain thanksgiving
Unum Therapeutics Announces Company Name Change to …
WebOct 5, 2024 · "Our new name reflects the evolution of our company to focus on developing precision therapies for genetically defined diseases and paves the path forward as we strive to deliver real solutions for patients in serious need of new treatment options," said Chuck Wilson, PhD, President and CEO of Cogent."Over the past three months, we have made … WebJul 7, 2024 · Unum Therapeutics is a biopharmaceutical company focused on developing a pipeline of novel therapies to treat cancer patients. Unum's most advanced program, PLX9486, is a highly potent and selective KIT D816V inhibitor that is being developed to treat systemic mastocytosis and GIST patients. Unum's cell therapy programs utilize … WebJul 6, 2024 · Chuck Wilson – President and CEO of Unum Therapeutics said: “Unum has explored a range of strategic alternatives through an orderly process to maximize shareholder value, and we believe this acquisition represents the highest-potential value creation opportunity for Unum stockholders. china new year sales